Skip to main content

TERAPIAS MOLECULARES DIRIGIDAS AL MICROAMBIENTE EN FIBROSIS Y CANCER

RTI2018-095672-B-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Mitochondrial damage, revealed as key factor in cabozantinib efficacy against hepatocellular carcinoma, is potentiated by the BH3-mimetic navitoclax

  • Tutusaus, Anna
  • Cucarull, Blanca
  • Rider, Patricia
  • Cuño-Gómiz, Carlos
  • García de Frutos, Pablo
  • Marí, Montserrat
  • Morales, Albert
Trabajo presentado en el International Liver Congress, celebrado en Londres y en formato online, del 22 al 26 de junio de 2022, The mitochondrial damage induced by sorafenib and regorafenib plays an important antitumor role in hepatocellular carcinoma (HCC). Both Tyrosine Kinase Inhibitors (TKIs) induce mitochondrial dependent cell death that may be potentiated by specific BH3-mimetics, selective inhibitors of BCL-2 proteins. ABT-263, navitoclax, is a BCL-2 and BCL-xL inhibitor studied in clinical trials, such as with sorafenib in solid tumors (NCT02143401). Mitochondrial effects of cabozantinib have not been previously reported in HCC therapy., This work was supported by grants from Instituto de Salud Carlos III (PI19/01410 to M.M.) and Ministerio de Ciencia e Innovación (RTI2018-095672-B-I00 to A.M./P.G.F.) and co-funded by FEDER (Fondo Europeo de Desarrollo Regional, Unión Europea); AGAUR (2017_SGR_177) and CERCA Programme/Generalitat de Catalunya